Cubist Systematic Strategies LLC Has $256,000 Holdings in FibroGen, Inc. (NASDAQ:FGEN)

Cubist Systematic Strategies LLC raised its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 3,906.9% during the second quarter, HoldingsChannel.com reports. The firm owned 287,332 shares of the biopharmaceutical company’s stock after acquiring an additional 280,161 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in FibroGen were worth $256,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Alpine Global Management LLC acquired a new stake in shares of FibroGen in the 1st quarter valued at approximately $25,000. Delap Wealth Advisory LLC acquired a new stake in shares of FibroGen in the 1st quarter valued at approximately $27,000. Accel Wealth Management acquired a new stake in shares of FibroGen in the 1st quarter valued at approximately $103,000. Point72 DIFC Ltd raised its position in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the period. Finally, Doheny Asset Management CA acquired a new stake in shares of FibroGen in the 2nd quarter valued at approximately $48,000. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of FibroGen in a research report on Sunday. They issued a “hold” rating on the stock.

FibroGen Price Performance

Shares of NASDAQ:FGEN opened at $0.34 on Tuesday. The firm’s 50 day simple moving average is $0.39 and its 200 day simple moving average is $0.89. FibroGen, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $2.93. The company has a market capitalization of $34.13 million, a price-to-earnings ratio of -0.14 and a beta of 0.70.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same quarter last year, the company earned ($0.65) EPS. Equities research analysts expect that FibroGen, Inc. will post -0.91 earnings per share for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.